blood product materials may contain numerous blood products , the isolation of some or all of which may be of medical or economic value . the present invention is directed toward a method of sequentially isolating multiple blood components from a single starting sample . more specifically , the discovery of the present invention is directed to methods of isolating one or more blood products from an lαlp - depleted blood product material . the lαlp family is a group of structurally related plasma - associated serine protease inhibitors . members of this family are composed of heavy and light polypeptide subunits that are covalently linked by a glycosaminoglycan . the light chain , also called bikunin , is responsible for the serine protease inhibitory activity of inter - alpha proteins . the name “ bikunin ” reflects the presence of two protease - inhibiting domains of the kunitz type . the heavy chains of inter - alpha proteins ( h1 , h2 , h3 , h4 ) are also called hyaluronic acid ( ha ) binding proteins . in normal plasma , bikunin is found mostly in a complex form as inter - alpha inhibitor ( lαl ), which has a molecular weight of about 225 to about 260 kda , and pre - alpha inhibitor ( pαl ), which has molecular weight of about 110 to about 130 kda . in lαl , bikunin is linked to 2 heavy polypeptide chains ( e . g ., h1 and h2 ), whereas , in pαl , only a single heavy chain ( e . g ., h3 ) is linked to bikunin . the lαlp - depleted blood product material may be produced by the use of a support to isolate lαlp ( e . g ., one or more ( e . g ., two , three , four , or more , or all ) lαlp family members , such as lαl , pαl , and / or bikunin , or both lαland pαl ) from a blood product material . in the present invention , lαlp may be isolated from a blood product material by any applicable method known in the art , including methods of chromatography , such as anion exchange chromatography , cation exchange chromatography , affinity chromatography , or dye - ligand chromatography . exemplary methods for the isolation of lαlp may be found in us20110190194 , which describes the use of deae chromatography with a low ph buffer , in particular a ph less than 4 . 0 ( e . g ., ph 4 . 0 , 3 . 7 , 3 . 5 , 3 . 4 , 3 . 3 , 3 . 1 , 2 . 9 , 2 . 0 ), to isolate lαlp . the method may involve more than one buffer step , where the subsequent buffer may have a lower ph than the first . the buffer may be acetic acid , sodium acetate , citric acid , glycine , phosphate or salt buffer . for example , the first buffer may be a salt buffer with a salt concentration of 290 mm nacl and the second buffer may have a ph of about 2 . 9 . us20110190194 is herein incorporated by reference . alternatively , us20120053113 describes the use of heparin affinity chromatography to isolate lαlp . additional methods of isolating lαlp are known in the art . the lαlp - depleted blood product material may include the flow - through from a support capable of capturing lαlp , such as a chromatography column . if a wash is applied to this support , the wash may be optionally included in the lαlp - depleted blood product material or , alternatively , be itself an lαlp - depleted blood product material . in some methods of the present invention , a blood product material may be admixed with a loading buffer before being applied to a support . a loading buffer of the present invention may be a buffer that permits or enhances the retention of one or more blood products on a support . a loading buffer of the present invention may also , or alternatively , decrease retention of contaminants on a support . a loading buffer may be a salt buffer of about 10 to about 300 mm salt , such as a salt buffer of about 10 , 20 , 30 , 40 , 50 , 100 , 120 , 140 , 160 , 180 , 200 , 220 , 240 , 260 , 280 or 300 mm salt . in particular embodiments , the support is a qa support and the loading buffer includes about 10 to 100 mm salt , such as 10 , 20 , 30 , 40 , 50 , 60 , 75 , 80 , 85 , 90 , 95 , or 100 mm salt . in some instances , the ph is from 5 . 5 to 6 . 5 , such as 5 . 5 , 5 . 7 , 5 . 9 , 6 . 0 , 6 . 1 , 6 . 3 , or 6 . 5 . in certain embodiments , the support is a qa support , the loading buffer includes about 50 mm salt , and the ph is about 6 . 0 . in particular embodiments , the support is a deaf support and the loading buffer includes about 150 to 250 mm salt , such as 150 , 175 , 200 , 225 , or 250 mm salt . in some instances , the ph is from 7 . 0 to 8 . 0 , such as 7 . 0 , 7 . 2 , 7 . 4 , 7 . 6 , 7 . 8 , or 8 . 0 . in certain embodiments , the support is a deaf support , the loading buffer includes about 200 mm salt , and the ph is about 7 . 6 . application of a blood product material admixed with a salt buffer may permit or enhance retention of lαlp while decreasing the retention of contaminants . other examples of loading buffers are known in the art . the lαlp - depleted blood product material may have in an lαlp family : igg weight ratio less than about 1 : 30 , such as about 1 : 40 , 1 : 50 , 1 : 100 , 1 : 200 , or 1 : 300 , and one of factor viii in a factor viii : lαlp family weight ratio greater than about 1 : 10 6 , such as about 1 : 10 5 , 1 : 10 4 , 1 : 10 3 , 1 : 10 2 , or 1 : 10 , and von willebrand factor in a von willebrand factor : lαlp family weight ratio greater than about 1 : 40 , such as 1 : 30 , 1 : 20 , 1 : 10 , 1 : 5 , or 1 : 1 . the present invention further relates to compositions required for or derived by the isolation of one or more blood products from an lαlp - depleted blood product material . blood products of the present invention include lαlp , albumin , iga , igg , igm , igd , igg , ivig , anti - d igg , hepatitis b igg , measles igg , rabies igg , tetanus igg , varicella zoster igg , fibrinogen ( factor i ), prothrombin ( factor ii ), factor iii , factor v , vii , factor viii , factor ix , factor x , factor xi , factor xii , factor xiii , fibronectin , alpha - 1 antitrypsin , alpha - 2 antiplasmin , urokinase , anti - thrombin iii , c1 - inhibitor , protein c , protein s , protein z , protein z - related protease inhibitor , plasminogen , tissue plasminogen activator , plasminogen activator inhibitor - 1 , plasminogen activator inhibitor - 2 , von willebrand factor , factor h , prekallikrein , high - molecular - weight kininogen , heparin cofactor ii , and thrombin . the inter - alpha inhibitor protein ( lαlp ) family is a group of plasma - associated serine protease inhibitors . members of this family are composed of heavy chain and light chain ( bikunin ) polypeptide subunits that are covalently linked by a glycosaminoglycan . in these heavy and light chain forms , bikunin remains inactive until its release by partial proteolytic degradation , a mechanism that serves as a means to regulate activity . lαlp may inhibit serine proteases that are involved in inflammation , e . g ., elastase , plasmin and cathepsin g . lαlp may be useful in the treatment of certain diseases and disorders , e . g ., sepsis , septic shock , endotoxic shock , disseminated intravascular coagulation , and fibroproliferation . albumin is the main protein of plasma . the primary biological function of albumin is to regulate the colloidal osmotic pressure of blood . albumin is capable of interacting with water , cations , fatty acids , hormones , bilirubin , thyroxine and other compounds . albumin may be used to treat patients with blood loss , shock , severe burns or other medical conditions . it can also be used as a component of cell growth media or as an excipient for pharmacologically active compounds . immunoglobulins , or antibodies , are endogenous proteins which circulate in the blood and perform diverse functions . they are critical to immune function . immunoglobulins are composed of four polypeptide chains , two light chains and two heavy chains . immunoglobulin types are determined by the heavy chain , and include igm , igd , igg , ige and iga . immunoglobulins may be further defined by their specific compositions or functions . clotting factors are blood proteins that control bleeding by directing the clotting process . circulating clotting factors are inactive , but injury initiates a coagulation cascade . the clotting process involves the contraction of blood vessels near a damaged area , followed by an accumulation of platelets . the platelets release chemical signals that result in the formation of a platelet plug . on the platelet surface , clotting factors form a fibrin clot . clotting factors include factors i ( fibrinogen ), ii ( prothrombin ), ill ( tissue factor ), iv ( calcium ), v ( labile factor ), vii ( stable factor ), viii ( antihemophilic factor a ), ix ( antihemophilic factor b ), x ( stuart prower factor ), xi ( antihemophilic factor c ), xii ( hageman factor ), and xiii ( fibrin stabilizing factor ). fibrinogen is a plasma glycoprotein converted to fibrin by thrombin in the presence of calcium ions . most of the fibrinogen found in blood is synthesized in the liver . during clotting , fibrin threads form a cross - linked meshwork that contributes to the formation of a blood clot . levels of fibrinogen increase in association with inflammation , hemostatic stress , pregnancy and other medical conditions . tissue factor is a cell surface glycoprotein . tissue factor interacts with stable factor , a serine protease , catalyzing the formation of thrombin from prothrombin . some cells release tissue factor in response to blood vessel damage . antihemophilic factor a is a glycoprotein cofactor that circulates in complex with von willebrand factor , from which it may be released by thrombin . separately , hageman factor , a serine protease , activates antihemophilic factor c , which in turn activates antihemophilic factor b . when thrombin dissociates antihemophilic factor a from von willebrand factor , antihemophilic factor a can interact with antihemophilic factor b in the presence of calcium ions and phospholipids to form a complex that activates stuart prower factor , a vitamin k - dependent serine protease . stuart prower factor cleaves prothrombin to yield active thrombin , potentiating coagulation . fibrin stabilizing factor is the protein responsible for stabilizing the formation of a blood clot . without it , blood clots form but break down , inhibiting wound healing . fibrin stabilizing factor is a thrombin - activated transglutaminase that functions by forming amide cross links between fibrin molecules . alpha - 1 antitrypsin is a protease inhibitor . its concentration in blood may rise upon inflammation . it protects tissues from enzymes of inflammatory cells and inhibits a wide variety of proteases . for instance , it inhibits neutrophil elastase that would otherwise break down elastin and potentially result in respiratory complications such as emphysema or chronic obstructive pulmonary disease in adults or cirrhosis in children . anti - thrombin ( iii ) is an inhibitor of the coagulation cascade . it is a protease that targets thrombin and factor x . inhibitors of coagulation such as heparin act , in part , through the potentiation of anti - thrombin . c1 - inhibitor protein is a protease inhibitor that prevents spontaneous activation of the complement system . its concentration in blood increases during inflammation . targets may include c1r and c1s of the c1 complex of the complement pathway , masp - 1 and masp - 2 of the mbl complexes of the lectin pathway , kallikrein , fxi , fxii , and proteases of fibrinolytic , clotting , or kinin pathways . the activity of c1 - inhibitor may indirectly prevent the cleavage of products such as c2 , c4 and mbl . protein c may also inhibit factors v and viii . protein c is a zymogenic serine protease that may be activated by binding of thrombin . upon activation , protein c may proteolytically inactivate factor v and factor viii . protein c contributes to the regulation of blood clotting , inflammation , and cell death . it also contributes to blood vessel permeability . because of the important role protein c plays as an anticoagulant , protein c deficiency increases the risk of thrombosis . von willebrand factor is critical to blood clotting . it is a glue - like protein that interacts with platelets to form a plug that directs blood flow at or near an injury . if this factor is lacking or abnormal , a bleeding disorder may result . factor h regulates the alternative complement pathway . it possesses three heparin - binding sites . mutation of factor h may result in atypical hemolytic uremic syndrome , a condition in which platelets are depleted . prothrombin is a trypsin - like serine protease glycoprotein with many functions . proteolysis of prothrombin may generate thrombin . thrombin is a protease that cleaves arg - gly bonds of fibrinogen , resulting in the formation of fibrin and the release of fibrinopeptides a and b . thrombin is part of the clotting cascade and contributes to the formation of a hemostatic plug . it potentiates coagulation by activating factors v , viii , xi and xiii . thrombin may also contribute to anticoagulation through interaction with thrombomodulin and activation of protein c . thrombin may also contribute to inflammation and wound healing activities , for instance by activation of neutrophils or platelets . the present application describes methods for isolating one or more blood products from an lαlp - depleted blood product material . the starting blood product material for the purification of blood products may be , for example , whole plasma , cryo - poor plasma , liquid plasma , fresh frozen plasma ( ffp ), ffp24 , frozen plasma ( fp ), fp24 , thawed ffp , thawed ffp24 , thawed fp , thawed fp24 , source plasma , recovered plasma , solvent / detergent - treated plasma ( sdp ), platelet - rich plasma ( prp ), platelet - poor plasma ( ppp ), serum , blood , or a diluted or concentrated preparation thereof . in a first step of some methods of the present invention , a blood product material may be contacted to a first support capable of retaining lαlp . for instance , a blood product material may be contacted to a deaf chromatography column , as described in us20110190194 , or to a heparin affinity chromatography column , as described in us20120053113 . the support of the present methods may be a support for a use in a method of chromatography , such as anion exchange chromatography , cation exchange chromatography , affinity chromatography , immunoaffinity chromatography , immobilized heparin chromatography , or dye - ligand chromatography . examples of chromatography devices that may be used in the methods of the present invention include deaf columns , such as deaf sepharose ® ( ge healthcare ), deaf ceramic hyperd ® ( pall , e . g ., 20067 - 0001 ), and fractogel ® emd deaf ( merck millipore , 1 . 16888 ). further examples include heparin affinity , such as heparin sepharose ® ( ge healthcare ), heparin hyper d ( pall , e . g ., 20029 - 021 ), and tskgel ® heparin ( tosoh , e . g ., 14444 ). alternatively , the support may be a support appropriate for nanofiltration . in some methods of the present invention , the support significantly retains the lαlp present in the blood product material . in a second step , a first flow - through is collected from the first support . the first flow - through is an lαlp - depleted blood product material substantially inclusive of one or more non - lαlp blood products . if the support is subsequently washed , the wash buffer flow - through may be included in the lαlp - depleted blood product or be itself an lαlp - depleted blood product . an lαlp - depleted blood product may comprise three or more , a majority , substantially all , or all of the non - lαlp blood product that were present in the starting blood product material . in some methods , lαlp may be eluted from the first support , producing a first eluate enriched with lαlp . this first eluate may also include a component of non - lαlp blood products . a variety of methods known in the art may be applied to further isolate lαlp . the percentage yield of lαlp that is isolated from a blood product material may be at least about 20 %, such as about 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 95 %, 99 %, or 100 %, of the total present in the blood product material . the yield of lαlp from a blood product material may be at least about 5 μg / ml , such as about 5 μg / ml , 10 μg / ml , 20 μg / ml , 30 μg / ml , 40 μg / ml , 50 μg / ml , 100 μg / ml , 200 μg / ml , 300 μg / ml , 400 μg / ml , 500 μg / ml , 1000 μg / ml , or 1500 μg / ml . in the present invention , at least one non - lαlp blood product is isolated from the lαlp - depleted blood product material . isolation of a non - lαlp blood product may involve applying the lαlp - depleted blood product material to a second support that captures one or more non - lαlp blood products , and subsequently eluting those products from the second support . methods for isolating non - lαlp blood products are known in the art . exemplary methods are provided below . albumin may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , us2011137283 describes the purification of albumin by diafiltration , u . s . pat . no . 4 , 156 , 681 describes the purification of albumin by alcohol extraction , and u . s . pat . no . 4 , 043 , 997 describes the purification of albumin by selective absorbance with a polyhydroxy polymer . in further examples , u . s . pat . no . 4 , 177 , 188 describes the purification of albumin by polyethylene glycol precipitation followed by thermocoagulation and u . s . pat . no . 4 , 086 , 222 describes the purification of albumin by chromatography . additional methods are also known in the art . immunoglobulins may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , usre31268 describes the purification of immunoglobulins by fractionated precipitation , us20120053325 describes the purification of immunoglobulins by dye - ligand affinity chromatography , and u . s . pat . no . 4 , 623 , 541 describes the purification of immunoglobulins by a two - step ammonium sulfate fractionation procedure employing centrifugation and ion depletion . in some methods known in the art , individual immunoglobulin types are isolated by techniques with specificity for one or more of igm , igd , igg , ige and iga , or particular immunoglobulins thereof . additional methods are also known in the art . factor i ( fibrinogen ) may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 7 , 041 , 790 describes the isolation of fibrinogen by an immobilized fibrinogen binding moiety conjugated to an affinity ligand . suzuki et al . ( thrombosis research , 18 : 707 - 715 , 1980 ) describes the isolation of fibrinogen by affinity chromatography with adsorption to a ristocetin - agarose column . fibrinogen may also be isolated by cryoprecipitation followed by chemical precipitation using ethanol or ammonium sulfate ( ismail , purification of fibrinogen from human plasma . chemical & amp ; biomolecular engineering theses , dissertations , & amp ; student research . 2012 ). additional methods are also known in the art . factor ii ( prothrombin ) may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 5 , 143 , 838 describes the isolation of prothrombin by anion exchange and us20120122179 describes the isolation of prothrombin by a deoxyribonucleic aptamer . additional methods are also known in the art . factor v may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , chiu et al . describes the isolation of factor v by polyethylene glycol precipitation followed by an immunoaffinity column ( chiu et al , j . clin invest . 72 : 493 - 503 , 1983 ) esnouf and jobin describe the isolation of factor v by adsorption to a phosphorylated cellulose column optionally followed by ultrafiltration ( esnouf and jobin , biochem . j . 102 : 660 - 665 , 1967 ). additional methods are also known in the art . factor vii may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , bajaj et al . describe the isolation of factor vii by adsorption onto barium citrate , followed by ammonium sulfate fractionation , deae - sephadex ® chromatography and preparative polyacrylamide gel electrophoresis ( bajaj et al ., j . biol . chem . 256 : 253 - 259 , 1981 ). kisiel and davie isolate factor vii by barium sulfate adsorption followed by elution deaf - sephadex ® batchwise adsorption and elution , benzamide - agarose column chromatography , heparin - agarose column chromatography and preparative polyacrylamide gel disc electrophoresis ( kisiel and davie , biochem . 14 : 4928 - 4934 , 1975 ). u . s . pat . no . 4 , 637 , 932 describes the isolation of factor vii using a divalent metal salt adsorbent followed by an anionic exchange resin . broze and majerus describe the isolation of factor vii by barium citrate adsorption and elution and ammonium sulfate fractionation followed by two steps of qae - sephadex ® column chromatography , sephadex ® g - 100 column chromatography , and gel filtration on a sephadex ® g - 25 column ( broze and majerus , j . biol . chem . 255 : 1242 - 1247 , 1980 ). hedner and kisiel describe the isolation of factor vii by deae - sepharose ® chromatography , ultra filtration , dialysis , qae - sephadex ® a - 50 chromatography , ultrafiltration , dialysis , and preparative electrophoresis ( hedner and kisiel , j clin . invest . 71 : 1836 - 1841 , 1983 ). additional methods are also known in the art . factor viii may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 4 , 758 , 657 describes the isolation of factor viii : c by adsorption onto a hydrophobic interaction matrix . u . s . pat . no . 4 , 798 , 675 describes the isolation of factor viii : c by adsorption onto a phospholipid coated support structure that is predominantly phosphatidylserine . u . s . pat . no . 4 , 789 , 733 describes the isolation of factor viii by precipitation with a sulphated polysaccharide , especially heparin . u . s . pat . no . 5 , 288 , 853 describes the isolation of factor viii complex using a heparin - coupled chromatographic medium , with further purification by precipitation with glycine and nacl . u . s . pat . no . 6 , 143 , 179 describes the isolation of factor viii by affinity - chromatography with immobilized cellular von - willebrand factor or a derivative thereof . u . s . pat . no . 5 , 259 , 951 describes the isolation of factor viii by ion exchange column chromatography . ep0317279 and u . s . pat . no . 4 , 361 , 509 describe the isolation of factor viii by immunoaffinity . u . s . pat . no . 4 , 758 , 657 describes the isolation of factor viii : c using a hydrophobic interaction matrix . u . s . pat . no . 5 , 245 , 014 describes the isolation of factor viii by gel filtration chromatography under group separation conditions . additional methods are also known in the art . factor ix may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 5 , 457 , 181 describes the isolation of factor ix by deae - sephadex ® chromatography followed successively by ion - exchange chromatography on deaf - sepharose ® and affinity chromatography on heparin - sepharose ®. u . s . pat . no . 5 , 919 , 909 describes the isolation of factor ix by a precipitation step , preferably using ammonium sulfate , leaving factor ix in the supernatant , from which it is further purified by chromatography . factor ix may also be isolated by a monoclonal antibody column , as described in u . s . pat . no . 6 , 732 , 716 . additional methods are also known in the art . factor x may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 5 , 378 , 365 describes the isolation of factor x by repeated ion exchange chromatographic separations followed by adsorption chromatography on metal ions . bajaj et al . describe a procedure for the purification of prothrombin , factor ix and factor x with the initial steps of adsorption onto and elution from barium citrate , ammonium sulfate fractionation and deae - sephadex ® chromatography followed by heparin - agarose chromatography carried out in a ( sodium ) citrate buffer of ph 7 . 5 ( bajaj et al . prep . biochem . 11 ( 4 ): 397 - 412 , 1981 ). additional methods are also known in the art . factor xi may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , us20100062512 describes the isolation of factor xi by hydrophobic charge induction chromatography . u . s . pat . no . 5 , 252 , 217 isolates factor xi by a filtration - adsorption step and a single step of chromatography on cation exchange resin . additional methods are also known in the art . factor xii may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , takahashi and saito describe the isolation of factor xii by monoclonal antibody - immunoaffinity column chromatography followed by gel filtration ( takahashi and saito , j . biochem . 103 : 641 - 643 , 1988 ). robin and colman describe the isolation of factor xii by ammonium sulfate fractionation , two zinc chelate sepharose ® affinity chromatography steps and gel filtration ( robin and colman , thrombosis res . 41 : 89 - 98 , 1986 ). chan and movat describe the isolation of factor xii by adsorption with aluminum hydroxide , precipitation with polyethylene glycol , anion exchange chromatography on qae - and a final step of either gel filtration on sephadex ® g - 100 or affinity chromatography on an immunoadsorbent column ( chan and movat , thrombosis res . 8 : 337 - 349 , 1976 ). additional methods are also known in the art . factor xiii may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 5 , 047 , 506 describes the isolation of factor xiii by affinity chromatography . us20080176789 describes the isolation of a factor xiii polypeptide by sequential anion exchange chromatography and hydrophobic interaction chromatography . u . s . pat . no . 5 , 688 , 919 describes the isolation of factor xiii by immunoaffinity chromatography . us20080281080 describes the isolation of factor xiii by immobilized metal affinity chromatography with optional further fractionation by various chromatography methods . u . s . pat . no . 5 , 204 , 447 describes the isolation of factor xiii by precipitation by adjusting the ph of a biological fluid to about ph 5 . 5 to 6 . 5 and recovering the precipitated factor xiii . additional methods are also known in the art . alpha - 1 antitrypsin may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , us20090292114 describes the purification of alpha - 1 antitrypsin by at least two metal chelate chromatography steps and cn101274956 describes the purification of alpha - 1 antitrypsin by precipitation , gel chromatography , and ultrafiltration . additional methods are also known in the art . anti - thrombin ( iii ) may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 3 , 842 , 061 describes the purification of anti - thrombin ( iii ) by adsorption onto a water - insoluble gel matrix comprised primarily of cross - linked sulfated carbohydrate and u . s . pat . no . 4 , 510 , 084 describes the purification of anti - thrombin ( iii ) by interaction with heparin or heparinoid followed by adsorption with an anion exchanger . additional methods are also known in the art . c1 - inhibitor protein may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 5 , 030 , 578 describes the purification of c1 - inhibitor protein by peg fractionation , jacalin - agarose chromatography and hydrophobic interaction chromatography on phenyl - sepharose ®. in another example , us07 / 815870 describes the isolation of c1 - inhibitor protein by antibody capture . additional methods are also known in the art . von willebrand factor may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 5 , 854 , 403 describes the isolation of von willebrand factor by quaternary amino anion exchange . u . s . pat . no . 7 , 939 , 643 describes the isolation of von willebrand factor by hydroxylapatite chromatography . additional methods are also known in the art . factor h may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , us20120053113 describes the purification of factor h by cryoprecipitation and anion exchange . additional methods are also known in the art . thrombin may be isolated from an lαlp - depleted blood product material by any applicable method known in the art , including precipitation , filtration , chromatography , liquid - solid extraction , and absorbance , or combinations thereof . for example , u . s . pat . no . 4 , 965 , 203 describes the purification of thrombin with a deaf agarose column . alternatively , thrombin may be produced from prothrombin that has been isolated from an lαlp - depleted blood product material . for example , u . s . pat . no . 5 , 393 , 666 and u . s . pat . no . 5 , 677 , 162 describe the treatment of prothrombin with calcium ions to yield thrombin and u . s . pat . no . 5 , 151 , 355 describes the treatment of prothrombin with thromboplastin in the presence of calcium , followed by filtration , an anion - exchange agarose column , and a cation - exchange agarose column to yield thrombin . in another example , u . s . pat . no . 5 , 432 , 062 describes the treatment of prothrombin with proteases in the presence of a detergent or certain chaotropic substances to produce thrombin . additional methods are also known in the art . isolation of a blood product may yield at least about 10 %, such as about 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, or 100 %, of the total amount of that blood product present in the starting blood product material . the yield of a particular blood product isolated from a blood product material will depend , in part , upon the quantity of that blood product present in the blood product starting material . in some instances , the yield of a blood product isolated from a blood product material may be at least about 1 μg / ml starting material , such as about 1 μg / ml , 5 μg / ml , 10 μg / ml , 20 μg / ml , 30 μg / ml , 40 μg / ml , 50 μg / ml , 60 μg / ml , 70 μg / ml , 80 μg / ml , 100 μg / ml , 200 μg / ml , 300 μg / ml , 400 μg / ml , 500 μg / ml , or 1 ng / ml . in some instances , the yield of a blood product isolated from a blood product material may be at least about 5 ng / ml starting material , such as about 10 ng / ml , 20 ng / ml , 30 ng / ml , 40 ng / ml , 50 ng / ml , 60 ng / ml , 70 ng / ml , 80 ng / ml , 100 ng / ml , 200 ng / ml , 300 ng / ml , 400 ng / ml , 500 ng / ml , or 1 μg / ml . in some instances , the yield of a blood product isolated from a blood product material may be at least about 5 μg / ml starting material , such as about 10 μg / ml , 20 μg / ml , 30 μg / ml , 40 μg / ml , 50 μg / ml , 60 μg / ml , 70 μg / ml , 80 μg / ml , 90 μg / ml , 100 μg / ml , 200 μg / ml , 300 μg / ml , 400 μg / ml , or 500 μg / ml , 1 mg / ml , 2mg / ml , 3 mg / ml , 4 mg / ml , 5 mg / ml , 6 mg / ml , 7 mg / ml , 8 mg / ml , 9 mg / ml , 10 mg / ml , 20 mg / ml , 30 mg / ml , 40 mg / ml , 50 mg / ml , 60 mg / ml , 70mg / ml , 80 mg / ml , 90 mg / ml , 100 mg / ml , 200 mg / ml , 500 mg / ml , or 1 g / ml starting material . the yield of a blood product isolated from a blood product material may also be in the range of at least about 1 μg / ml to at least about 1 g / ml . in addition to methods of isolating one or more blood products from an lαlp - depleted blood product material , the invention also features compositions that may be produced through the described methods . one of these compositions is an lαlp - depleted blood product material . isolated blood products are known to treat particular medical conditions . blood products isolated by the methods of the present invention , including lαlp , may be useful in the treatment of such conditions . pharmaceutical compositions of blood products isolated by the methods of the present invention may be administered or provided to a subject in need in a pharmaceutically acceptable dosage . in one example of the present invention , von willebrand factor is isolated from lαlp - depleted ffp24 . ffp24 is thawed and diluted 1 : 10 in plasma dilution buffer ( 25 mm tris , 200 mm nacl , ph 7 . 6 ) and applied to a deae monolithic column . the flow - through is collected and additional plasma dilution buffer is applied to allow the starting material to pass through the column completely . the additional plasma dilution buffer may then be included with the flow - through . when the flow - through peak returns to baseline , the column is washed with low ph buffer ( 150 mm acetic acid , ph 4 . 0 , or 200 mm acetic acid , ph 3 . 3 ) and the peak is collected . after the low ph wash , the column is further washed with a higher ph buffer ( 100 mm tris , 100 mm nacl , ph 7 . 6 ) to restore the ph . bound protein is eluted with a high salt elution buffer ( 25 mm tris , 1000 mm nacl , ph 7 . 6 ). the peak is collected and this fraction contains highly pure lαlp . lαlp may then be further purified to exchange buffer and remove low molecular weight solutes and salts by ultrafiltration or diafiltration using a membrane cut off of 30 kda . von willebrand factor is isolated from the flow - through . the flow - through is filtered over an anion exchanger column ( emd - tmae - fractogel ® ( merck )) that has been equilibrated with buffer ( 20 mm tris - hcl , ph 7 . 4 ). subsequently , the column is washed with additional buffer . foreign materials are removed by washing the column with 200 mm nacl buffer . the von willebrand factor is then eluted from the column with another buffer ( 280 mm nacl 20 mm tris - hcl , ph 7 . 4 ). subsequently , residual material , which is possibly present , is eluted from the column with 1m nacl . in a second example of the present invention , albumin is isolated from lαlp - depleted cryo - poor plasma . cryo - poor plasma is diluted 1 : 10 in dilution buffer ( 40 mm tris , 200 mm nacl , ph 7 . 6 ) and applied to a deae monolithic column . the flow - through is collected and additional buffer ( 25 mm tris , 200 mm nacl , ph 7 . 6 ) is applied to the column to allow the starting material to pass through the column completely . the additional buffer may then be included with the first flow - through . when the flow - through peak returns to baseline , the column is washed with salt - containing wash buffer ( 40 mm tris - hcl , 290 mm nacl , ph 7 . 6 ) and the peak is collected . after the salt wash , the column is additionally washed with low ph buffer ( 200 mm na - acetate , ph 2 . 95 ) and the peak is collected . following the second wash , bound protein is eluted with high salt elution buffer ( 40 mm na - citrate , 1000 mm nacl , ph 6 . 50 ). the peak is collected ; this fraction contains highly pure lαlp . albumin is isolated from the flow - through . the flow - through is applied to a deae - sephadex ® a - 50 ( deae - substituted cross - linked dextran ) that has been allowed to swell in 0 . 075 m nacl solution and has been decanted 3 times , autoclaved at 121 ° c . for 0 . 5 hours , washed with 1 m nacl , and suspended in 0 . 075 m nacl . the suspension is stirred for 45 minutes and then the deae - sephadex ® a - 50 gel is filtered off , whereas the filtrate is frozen and stored at − 20 ° c . this frozen suspension is thawed at + 4 ° c . and adjusted to ph 8 . 0 with 0 . 5 m naoh solution , after which polyethylene glycol 4000 ( mw 3000 - 3700 ) is added to the ph adjusted plasma fraction . after stirring for 30 minutes at + 4 ° c ., the precipitate is removed by centrifugation at 1800 g for 10 minutes at + 4 ° c . the supernatant is adjusted to ph 4 . 8 with 0 . 5m hcl at + 4 ° c ., and additional polyethylene glycol 4000 is added to a final concentration of 22 % ( w / v ). the mixture is stirred at + 4 ° c . for 30 minutes and the albumin containing precipitate is collected by centrifugation at 1800 g for 10 minutes at + 4 ° c . the precipitate is dissolved at + 4 ° c . in distilled water and ph is adjusted to 7 . 0 with 0 . 5 m naoh . the solution contains the albumin . further purification of albumin is optionally achieved by application to an anion exchanger followed by application to a cation exchanger . in a third example of the present invention , alpha - 1 antitrypsin is isolated from lαlp - depleted whole plasma . whole plasma is diluted 1 : 10 in dilution buffer ( 40 mm tris , 200 mm nacl , ph 7 . 6 ) and applied to a deae monolithic column . the flow - through is collected and additional buffer ( 25 mm tris , 200 mm nacl , ph 7 . 6 ) is applied to the column to allow the starting material to pass through the column completely . the additional buffer may then be included with the first flow - through . when the flow - through peak returns to baseline , the column is washed with salt - containing wash buffer ( 40 mm tris - hcl , 290 mm nacl , ph 7 . 6 ) and the peak is collected . after the salt wash , the column is additionally washed with low ph buffer ( 200 mm na - acetate , ph 2 . 95 ) and the peak is collected . following the second wash , bound protein is eluted with high salt elution buffer ( 40 mm na - citrate , 1000 mm nacl , ph 6 . 50 ). the peak is collected ; this fraction contained highly pure lαlp . to isolate alpha - 1 antitrypsin from the flow - through , the flow - through is frozen and subjected to a controlled thaw at − 0 . 5 ° c . to 2 ° c . during which some proteins precipitate . the supernatant is collected , treated with celite ®, and then filtered to remove unwanted proteins . the resulting supernatant is adjusted to a ph of 5 . 85 with acetate buffer and ethanol is added to 17 - 21 % v / v . the temperature of the ensuing precipitation is maintained between − 4 ° c . and − 6 ° c ., such that the precipitate includes fraction 1 and precipitate a of the kistler and nitschmann process ( ibid ). the supernatant is diluted 1 : 1 with buffer ( 10 mm nah 2 po 4 , 10 mm naoh , ph 11 ). the ph of the resulting solution is between 6 and 7 with conductivity less than 7 ms / cm . ph is reduced to between 5 . 5 and 6 . 5 with dilute acetic acid just prior to loading onto a capto q sepharose ® column equilibrated with buffer ( 20 mm phosphate , 30 mm nacl , ph 6 . 2 ). alpha - 1 antitrypsin is then eluted with buffer ( 20 mm phosphate containing 170 mm nacl , ph 6 . 2 ). 2 . 5 mm of imidazole is added to the alpha - 1 antitrypsin fraction eluted from the capto q column , which is then loaded onto a histrap column stripped of its nickel ions and re - charged with divalent copper cations . at this imidazole concentration and using this type of chelating solid support , some contaminants , but not alpha - 1 antitrypsin , bind to the solid support . the flow - through thus contains alpha - 1 antitrypsin . to reduce the viral load of the alpha - 1 antitrypsin fraction , a polysorbate 20 / tri - n - butyl phosphate mixture is added according to ep - a 0131740 . the solvent detergent ( sd ) treated alpha - 1 antitrypsin fraction is loaded onto a chelating sepharose ® solid support ( iminodiacetic acid chelating ligand ) charged with copper . under the conditions of the load ( 2 . 5 mm imidazole in 20 mm phosphate buffer containing 30 mm nacl , ph 6 . 2 ) the alpha - 1 antitrypsin is bound by the solid support whilst contaminants are not . the alpha - 1 antitrypsin is then eluted with 10 mm imidazole solution . all publications , patent applications , and patents mentioned in this specification are herein incorporated by reference . while the invention has been described in connection with the specific embodiments , it will be understood that it is capable of further modifications . therefore , this application is intended to cover any variations , uses , or adaptations of the invention that follow , in general , the principles of the invention , including departures from the present disclosure that come within known or customary practice within the art .